Diagnostic Center | December 15, 2022
Biocon initiates clinical study of Itolizumab for ulcerative colitis in India
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
It is a two dose vaccine to be administered intramuscularly at 28 days apart
The procedures have been performed by Dr. Kaushal Pandey at P.D. Hinduja Hospital in Mumbai, India
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)
The approval comes soon after Corbevax was given the nod for 12-15-year group
The minister exhorted the pharmaceutical sector to prepare a plan for the next 25 years
Sputnik Light is the first component of Sputnik V
Subscribe To Our Newsletter & Stay Updated
